Source comparison
BPC-157 for Lyme Disease Researchers: Comparison
Peripheral neuropathy (nerve pain, numbness) Upregulates VEGF and nerve growth factor; promotes Schwann cell proliferation and myelin repair Rat sciatic nerve crush model: 38% faster nerve conduction recovery vs control (2023 study) No controlled trials; anecd
This comparison does not assign a generated winner or score.
- Peripheral neuropathy (nerve pain, numbness)
- Upregulates VEGF and nerve growth factor; promotes Schwann cell proliferation and myelin repair
- Rat sciatic nerve crush model: 38% faster nerve conduction recovery vs control (2023 study)
- No controlled trials; anecdotal off-label use only
- Most plausible application. Mechanism directly addresses nerve damage seen in late-stage Lyme
- Lyme arthritis (joint inflammation)
- Reduces IL-1β and TNF-alpha; inhibits MMP-3/MMP-13 cartilage degradation
- Mouse collagen-induced arthritis: 44% reduction in synovial inflammation vs control (2022 study)
- No controlled trials; some observational case reports
- Promising but less specific. Standard DMARDs target the same pathways with more clinical data
- Gut-brain axis dysfunction (PTLDS cognitive symptoms)
- Stabilises intestinal tight junctions; modulates vagal nerve signaling
- Rat models of gut permeability: reduced LPS translocation by 52% (2021 study)
- No controlled trials; exploratory protocols only
- Hypothesis-driven. Mechanism aligns with systemic inflammation in PTLDS but lacks direct Lyme evidence
- Cardiac involvement (Lyme carditis)
- Promotes angiogenesis and reduces fibrosis in cardiac tissue
- Rat models of doxorubicin-induced cardiotoxicity: improved ejection fraction by 22% (2020 study)
- No trials; not used clinically for Lyme carditis
- Weak rationale. Lyme carditis is rare and resolves with antibiotics; tissue damage is minimal